Logistics of Adopting 177Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting.

IF 1 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of nuclear medicine technology Pub Date : 2025-03-05 DOI:10.2967/jnmt.124.268039
Kathleen Marsh, Kayla Allickson, Amanda Jesz, Cheryl Hanson, Donna Newman, Erica Martin-Macintosh
{"title":"Logistics of Adopting <sup>177</sup>Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting.","authors":"Kathleen Marsh, Kayla Allickson, Amanda Jesz, Cheryl Hanson, Donna Newman, Erica Martin-Macintosh","doi":"10.2967/jnmt.124.268039","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, <sup>177</sup>Lu-vipivotide tetraxetan was U.S. Food and Drug Administration-approved for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. <b>Methods:</b> Although preliminary data for <sup>177</sup>Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating <sup>177</sup>Lu-vipivotide tetraxetan into non-academic-based clinical practices. <b>Results:</b> This article presents a multidisciplinary practice implementation workflow for <sup>177</sup>Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. <b>Conclusion:</b> The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically <sup>177</sup>Lu-vipivotide tetraxetan.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"68-71"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnmt.124.268039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, 177Lu-vipivotide tetraxetan was U.S. Food and Drug Administration-approved for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. Methods: Although preliminary data for 177Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating 177Lu-vipivotide tetraxetan into non-academic-based clinical practices. Results: This article presents a multidisciplinary practice implementation workflow for 177Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. Conclusion: The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically 177Lu-vipivotide tetraxetan.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of nuclear medicine technology
Journal of nuclear medicine technology RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
1.90
自引率
15.40%
发文量
57
期刊最新文献
Delivery Methods of Radiopharmaceuticals: Exploring Global Strategies to Minimize Occupational Radiation Exposure. Effectiveness of Data-Driven Gating FDG PET/CT for Abdominal Region. Fitness for Purpose of Text-to-Image Generative Artificial Intelligence Image Creation in Medical Imaging. [18F]FDG PET/CT in Metastatic Extragonadal Choriocarcinoma. Software Discrepancies in Radionuclide-Derived Left Ventricular Ejection Fraction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1